Durable Responses to JCAR017 Observed in High-Risk DLBCL
2018-03-29 10:30:12
Responses to lisocabtagene maraleucel have been potent and durable in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma. Separate exploratory analyses of this population treated with liso-cel found that high tumor burden and a series of in ammatory biomarkers were associated with high chimeric antigen receptor T-cell expansion and higher rates of cytokine release syndrome and neurotoxicity.
Leave a Reply
Want to join the discussion?Feel free to contribute!